Dublin, April 02, 2026 (GLOBE NEWSWIRE) — The “Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Report 2026” has been added to ResearchAndMarkets.com’s offering. The report offers a comprehensive analysis of current and future industry scenarios.
The Programmed Death (PD-1) Non-Small Cell Lung Cancer (NSCLC) market has witnessed significant growth recently and is poised to expand further. From a size of $27.5 billion in 2025, it’s anticipated to reach $29.92 billion in 2026, marking a CAGR of 8.8%. This growth is primarily due to the limited PD-1 inhibitors approved for NSCLC, a rising incidence of lung cancer, and increased awareness among physicians about immune checkpoint therapies. Companies are leveraging the success of drugs like pembrolizumab and nivolumab, along with a continued reliance on chemotherapy.
Looking ahead, the market is projected to reach $41.45 billion by 2030, forecasting a CAGR of 8.5%. Key drivers include the development of novel combination therapies and the expansion of biomarker-driven personalized treatments. Furthermore, the increasing adoption of mRNA vaccine-based therapies and substantial investments in immuno-oncology research contribute to the market growth. Trends to watch include the increasing use of PD-1 monotherapy, advancements in combination therapies, and a focus on personalized medicine through biomarker testing.
Personalized treatments, tailored to an individual’s genetic profile and disease characteristics, are fueling market expansion by enabling more targeted and effective therapies. For example, in February 2024, the Personalized Medicine Coalition noted the FDA approved 16 new personalized treatments for rare diseases, a significant increase from previous years. This trend underscores the impact of personalized medicine in driving the NSCLC market.
Market leaders are engaged in innovative clinical trials, focusing on therapies like monotherapy, to achieve better patient outcomes. A case in point is Akeso, Inc.’s announcement in March 2025 regarding its Phase III HARMONi-2 trial results. The trial explored Ivonescimab in combination with chemotherapy, proving its effectiveness over pembrolizumab in extending progression-free survival, showcasing the potential of this therapeutic approach.
Notable acquisitions are also shaping the market landscape. In February 2025, BioNTech SE acquired Biotheus Inc., gaining access to PM8002, a promising bispecific antibody targeting PD-L1 and VEGF-A, with potential applications in NSCLC and other tumors. This strategic move highlights the ongoing industry consolidation and collaboration efforts.
Key players in the PD-1 NSCLC market include F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Sanofi S.A., Novartis AG, GlaxoSmithKline plc, Regeneron Pharmaceuticals Inc., among others. With North America leading, Asia-Pacific is predicted to emerge as the fastest-growing region. Countries such as the USA, Canada, China, and Germany are crucial markets for this industry.
Reasons to Purchase:
- Gain a comprehensive, global perspective with coverage across 16 geographies.
- Analyze the influence of macro factors including geopolitical tensions, trade policies, inflation, and regulatory changes.
- Develop tailored regional and country strategies using localized data and analysis.
- Identify profitable growth segments for strategic investment decisions.
- Leverage forecast data and trends to stay ahead of competitors.
- Enhance understanding of consumer behaviors through end-user analysis.
- Benchmark against competitors using metrics on market share, innovation, and brand strength.
- Access reliable, high-quality data for effective internal and external presentations, complete with Excel data sheets for ease of use.
Report Scope
Markets Covered:
- Drug Type (Monotherapy, Combination Therapy)
- Line of Therapy (First-line, Second-line and Beyond)
- End User (Hospitals, Specialty Centers, Academic Institutes)
Subsegments: Detailed categorization based on drug types and combination therapies.
Companies Mentioned: Notable industry leaders such as F. Hoffmann-La Roche Ltd, Merck & Co. Inc., and others.
Countries: Australia, Brazil, China, France, Germany, India, and more.
Regions: Comprehensive coverage across global regions including Asia-Pacific, North America, and Western Europe.
Data and Delivery: Detailed data segmentation with country and regional forecasts, available in Word, PDF, and Interactive formats.
Key Attributes
| Report Attribute | Details |
| No. of Pages | 250 |
| Forecast Period | 2026-2030 |
| Estimated Market Value (USD) in 2026 | $29.92 Billion |
| Forecasted Market Value (USD) by 2030 | $41.45 Billion |
| Compound Annual Growth Rate | 8.5% |
| Regions Covered | Global |
The companies featured in this Programmed Death (PD)-1 Non-Small Cell Lung Cancer market report include:
- F. Hoffmann-La Roche Ltd.
- Merck & Co. Inc.
- Sanofi S.A.
- Novartis AG
- GlaxoSmithKline plc
- Regeneron Pharmaceuticals Inc.
- Incyte Corporation
- Ono Pharmaceutical Co. Ltd.
- BeiGene Ltd.
- BioNTech SE
- Shanghai Junshi Biosciences Co. Ltd.
- Akeso Inc.
- Arcus Biosciences Inc.
- Shandong Boan Biotechnology Co. Ltd.
- CStone Pharmaceuticals
- iTeos Therapeutics Inc.
- Summit Therapeutics Inc.
- Shanghai Henlius Biotech Inc.
For more information about this report visit https://www.researchandmarkets.com/r/isult
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
- Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market
